NYMC Faculty Publications
Novel Agents for Advanced Pancreatic Cancer
Author Type(s)
Faculty
DOI
10.18632/oncotarget.3999
Journal Title
Oncotarget
First Page
39521
Last Page
39537
Document Type
Article
Publication Date
11-24-2015
Department
Medicine
Keywords
Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, Humans, Immunoconjugates, Pancreatic Neoplasms, Signal Transduction, Small Molecule Libraries, Survival Analysis, Treatment Outcome
Disciplines
Medicine and Health Sciences
Abstract
Pancreatic cancer is relatively insensitive to conventional chemotherapy. Therefore, novel agents targeting dysregulated pathways (MAPK/ERK, EGFR, TGF-β, HEDGEHOG, NOTCH, IGF, PARP, PI3K/AKT, RAS, and Src) are being explored in clinical trials as monotherapy or in combination with cytotoxic chemotherapy. This review summarizes the most recent advances with the targeted therapies in the treatment of patients with advanced pancreatic cancer.
Recommended Citation
Akinleye, A., Iragavarapu, C., Furqan, M., Cang, S., & Liu, D. (2015). Novel Agents for Advanced Pancreatic Cancer. Oncotarget, 6 (37), 39521-39537. https://doi.org/10.18632/oncotarget.3999
